查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2032334

抗體藥物複合體市場報告：按成分、標靶、應用、最終用戶和地區分類（2026-2034 年）

Antibody Drug Conjugates Market Report by Component, Target, Application, End User, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 145 Pages | 商品交期: 2-3個工作天內

價格

2025年全球抗體藥物偶聯物（ADC）市場規模達112億美元。展望未來，IMARC Group預測，該市場從2026年到2034年將以18.68%的複合年成長率成長，到2034年達到548億美元。

抗體藥物偶聯物（ADC）是一種高效的生技藥品，其細胞毒性效應分子透過化學方式與標靶腫瘤的抗體結合。 ADC透過可生物分解的連接子與單株抗體（mAb）偶聯，能夠精準區分健康組織和病變組織，並將細胞毒性抗癌藥物遞送至受累細胞。與標準化療藥物相比，ADC有助於增強mAb的細胞殺傷能力，提高藥物耐受性，並減少全身暴露。目前，ADC主要透過靜脈注射進入血液，以防止mAb被胃酸和蛋白水解酶分解。

抗唑類藥物偶聯物市場趨勢

由於久坐的生活方式以及吸煙和飲酒習慣的日益普遍，全球癌症發病率正在上升。此外，對經濟有效的癌症治療方法日益成長的需求也是市場成長的主要驅動力。另一方面，現有的連接子通常無法針對特定標靶釋放藥物，導致脫靶毒性，嚴重影響抗體藥物偶聯物（ADC）的開發。因此，領導企業正持續投資研發項目，以最佳化現有化學觸發器並開發新型化學觸發器，從而產生高選擇性連接子。他們也正在設計新型連接子-抗體偶聯方法，以生產穩定且均一的ADC，以及額外的連接子-有效載荷偶聯方法，以實現有效載荷的擴展。此外，他們還致力於改善吸收、分佈、代謝和排泄（ADME）過程，這為市場帶來了良好的前景。預計推動市場成長的其他關鍵因素包括醫療基礎設施的顯著改善、人們對現有癌症治療方案的認知不斷提高以及可裂解連接子技術的引入。

本報告解答的關鍵問題

  • 迄今為止，全球抗體藥物偶聯物市場的發展趨勢是什麼？您預計未來幾年該市場將如何發展？
  • 新冠疫情對全球抗體藥物偶聯物市場產生了哪些影響？
  • 主要區域市場有哪些？
  • 市場按組成部分是如何分類的？
  • 按目標群體分類的市場區隔如何？
  • 按應用領域分類的市場區隔如何？
  • 依最終用戶分類的市場區隔如何？
  • 該產業價值鏈包含哪些不同階段？
  • 該行業的主要促進因素和挑戰是什麼？
  • 全球抗體藥物偶聯物市場的結構是怎麼樣的？主要參與企業有哪些？
  • 該行業的競爭有多激烈？

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球抗體藥物偶聯物市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依組件分類

  • 單株抗體
  • 連接器
  • 細胞毒性藥物
  • 其他

第7章 市場區隔：依目標群體分類

  • 抗體-蛋白毒素複合物
  • 抗體螯合放射性核種複合物
  • 抗體-小分子藥物偶聯物
  • 抗體-酵素複合物

第8章 市場區隔：依應用領域分類

  • 淋巴瘤
  • 卵巢癌
  • 肺癌
  • 乳癌
  • 腦腫瘤
  • 其他

第9章 市場區隔：依最終用戶分類

  • 醫院
  • 專科癌症中心
  • 學術研究機構
  • 生技公司
  • 其他

第10章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第11章 SWOT 分析

第12章：價值鏈分析

第13章：波特五力分析

第14章：價格分析

第15章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • ADC Therapeutics SA
    • Astellas Pharma Inc.
    • AstraZeneca plc
    • Celldex Therapeutics Inc.
    • F. Hoffmann-La Roche AG
    • Gilead Sciences Inc.
    • GlaxoSmithKline Plc
    • ImmunoGen Inc
    • Pfizer Inc.
    • Sanofi SA
    • Seagen Inc.
    • Sorrento Therapeutics Inc.
    • Takeda Pharmaceutical Company Ltd.
Product Code: SR112026A4604

The global antibody drug conjugates market size reached USD 11.2 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 54.8 Billion by 2034, exhibiting a growth rate (CAGR) of 18.68 % during 2026-2034.

Antibody drug conjugates (ADCs) are highly potent biological drugs comprising tumor-targeting antibodies, which are chemically attached to a cytotoxic effector molecule. They deliver cytotoxic anticancer agents to affected cells by connecting them to monoclonal antibodies (mAb) through biodegradable linkers and allowing sensitive bifurcation between healthy and diseased tissues. They assist in increasing the cell-killing potential of mAb, enhancing drug tolerability, and limiting systematic exposure compared to standard chemotherapy bioactive compounds. At present, they are administered intravenously into the bloodstream to avoid gastric acid and proteolytic enzyme degradation of the mAb.

ANTIBODY DRUG CONJUGATES MARKET TRENDS:

Due to sedentary lifestyles and the rising number of individuals who smoke and drink regularly, there is an increase in the prevalence of cancer around the world. This, in confluence with the escalating demand for cost-effective and successful cancer treatments, represents one of the key factors bolstering the growth of the market. Apart from this, the existing linkers often release payloads nonspecifically and lead to off-target toxicity, which severely affects the development of ADCs. As a result, leading players are continuously funding their research and development (R&D) projects to optimize the existing chemical triggers and develop novel chemical triggers to generate highly selective linkers. They are also coming up with novel linker-antibody attachments to produce stable and homogenous ADCs and additional linker-payload attachments to allow the expansion of payloads. Moreover, they are focusing on improving the absorption, distribution, metabolism, and excretion, which is creating a favorable market outlook. Other major factors, including considerably improving healthcare infrastructure, increasing awareness about therapies available for cancer treatments, and the introduction of cleavable linker technology, are anticipated to propel the market growth.

KEY MARKET SEGMENTATION:

Breakup by Component:

  • Monoclonal Antibodies
  • Linker
  • Cytotoxic Agent
  • Others

Breakup by Target:

  • Antibody-Protein Toxin Conjugates
  • Antibody-Chelated Radionuclide Conjugates
  • Antibody-Small-Molecule Drug Conjugates
  • Antibody-Enzyme Conjugates

Breakup by Application:

  • Lymphoma
  • Ovarian Cancer
  • Lung Cancer
  • Breast Cancer
  • Brain Tumor
  • Others

Breakup by End User:

  • Hospitals
  • Specialized Cancer Centers
  • Academic Research Institutes
  • Biotechnology Companies
  • Others

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

COMPETITIVE LANDSCAPE:

The competitive landscape of the industry has also been examined along with the profiles of the key players being ADC Therapeutics SA, Astellas Pharma Inc., AstraZeneca plc, Celldex Therapeutics Inc., F. Hoffmann-La Roche AG, Gilead Sciences Inc., GlaxoSmithKline Plc, ImmunoGen Inc, Pfizer Inc., Sanofi S.A., Seagen Inc., Sorrento Therapeutics Inc. and Takeda Pharmaceutical Company Ltd.

KEY QUESTIONS ANSWERED IN THIS REPORT

  • How has the global antibody drug conjugates market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global antibody drug conjugates market?
  • What are the key regional markets?
  • What is the breakup of the market based on the component?
  • What is the breakup of the market based on the target?
  • What is the breakup of the market based on the application?
  • What is the breakup of the market based on the end user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global antibody drug conjugates market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Antibody Drug Conjugates Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Component

  • 6.1 Monoclonal Antibodies
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Linker
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Cytotoxic Agent
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Target

  • 7.1 Antibody-Protein Toxin Conjugates
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Antibody-Chelated Radionuclide Conjugates
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Antibody-Small-Molecule Drug Conjugates
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Antibody-Enzyme Conjugates
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Lymphoma
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Ovarian Cancer
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Lung Cancer
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Breast Cancer
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Brain Tumor
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Others
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Specialized Cancer Centers
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Academic Research Institutes
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Biotechnology Companies
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Others
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 ADC Therapeutics SA
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
    • 15.3.2 Astellas Pharma Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 AstraZeneca plc
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Celldex Therapeutics Inc.
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 F. Hoffmann-La Roche AG
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
    • 15.3.6 Gilead Sciences Inc.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 GlaxoSmithKline Plc
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 ImmunoGen Inc
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Pfizer Inc.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Sanofi S.A.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Seagen Inc.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 Sorrento Therapeutics Inc.
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
    • 15.3.13 Takeda Pharmaceutical Company Ltd.
      • 15.3.13.1 Company Overview
      • 15.3.13.2 Product Portfolio
      • 15.3.13.3 Financials
      • 15.3.13.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Antibody Drug Conjugates Market: Major Drivers and Challenges
  • Figure 2: Global: Antibody Drug Conjugates Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Antibody Drug Conjugates Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Antibody Drug Conjugates Market: Breakup by Component (in %), 2025
  • Figure 5: Global: Antibody Drug Conjugates Market: Breakup by Target (in %), 2025
  • Figure 6: Global: Antibody Drug Conjugates Market: Breakup by Application (in %), 2025
  • Figure 7: Global: Antibody Drug Conjugates Market: Breakup by End User (in %), 2025
  • Figure 8: Global: Antibody Drug Conjugates Market: Breakup by Region (in %), 2025
  • Figure 9: Global: Antibody Drug Conjugates (Monoclonal Antibodies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 10: Global: Antibody Drug Conjugates (Monoclonal Antibodies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 11: Global: Antibody Drug Conjugates (Linker) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Antibody Drug Conjugates (Linker) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Antibody Drug Conjugates (Cytotoxic Agent) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Antibody Drug Conjugates (Cytotoxic Agent) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Antibody Drug Conjugates (Other Components) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Antibody Drug Conjugates (Other Components) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Antibody Drug Conjugates (Antibody-Protein Toxin Conjugates) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Antibody Drug Conjugates (Antibody-Protein Toxin Conjugates) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Antibody Drug Conjugates (Antibody-Chelated Radionuclide Conjugates) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Antibody Drug Conjugates (Antibody-Chelated Radionuclide Conjugates) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: Antibody Drug Conjugates (Antibody-Small-Molecule Drug Conjugates) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: Antibody Drug Conjugates (Antibody-Small-Molecule Drug Conjugates) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Global: Antibody Drug Conjugates (Antibody-Enzyme Conjugates) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Global: Antibody Drug Conjugates (Antibody-Enzyme Conjugates) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: Global: Antibody Drug Conjugates (Lymphoma) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: Global: Antibody Drug Conjugates (Lymphoma) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: Global: Antibody Drug Conjugates (Ovarian Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: Global: Antibody Drug Conjugates (Ovarian Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: Global: Antibody Drug Conjugates (Lung Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: Global: Antibody Drug Conjugates (Lung Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: Global: Antibody Drug Conjugates (Breast Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: Global: Antibody Drug Conjugates (Breast Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: Global: Antibody Drug Conjugates (Brain Tumor) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: Global: Antibody Drug Conjugates (Brain Tumor) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: Global: Antibody Drug Conjugates (Other Applications) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: Global: Antibody Drug Conjugates (Other Applications) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: Global: Antibody Drug Conjugates (Hospitals) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: Global: Antibody Drug Conjugates (Hospitals) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: Global: Antibody Drug Conjugates (Specialized Cancer Centers) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: Global: Antibody Drug Conjugates (Specialized Cancer Centers) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: Global: Antibody Drug Conjugates (Academic Research Institutes) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: Global: Antibody Drug Conjugates (Academic Research Institutes) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: Global: Antibody Drug Conjugates (Biotechnology Companies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: Global: Antibody Drug Conjugates (Biotechnology Companies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: Global: Antibody Drug Conjugates (Other End Users) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: Global: Antibody Drug Conjugates (Other End Users) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: North America: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: North America: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: United States: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: United States: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: Canada: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: Canada: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: Asia-Pacific: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: Asia-Pacific: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: China: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: China: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: Japan: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: Japan: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: India: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: India: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: South Korea: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: South Korea: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: Australia: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: Australia: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: Indonesia: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: Indonesia: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 67: Others: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 68: Others: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 69: Europe: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 70: Europe: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 71: Germany: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 72: Germany: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 73: France: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 74: France: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 75: United Kingdom: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 76: United Kingdom: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 77: Italy: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 78: Italy: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 79: Spain: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 80: Spain: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 81: Russia: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 82: Russia: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 83: Others: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 84: Others: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 85: Latin America: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 86: Latin America: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 87: Brazil: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 88: Brazil: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 89: Mexico: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 90: Mexico: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 91: Others: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 92: Others: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 93: Middle East and Africa: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 94: Middle East and Africa: Antibody Drug Conjugates Market: Breakup by Country (in %), 2025
  • Figure 95: Middle East and Africa: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 96: Global: Antibody Drug Conjugates Industry: SWOT Analysis
  • Figure 97: Global: Antibody Drug Conjugates Industry: Value Chain Analysis
  • Figure 98: Global: Antibody Drug Conjugates Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Antibody Drug Conjugates Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Antibody Drug Conjugates Market Forecast: Breakup by Component (in Million USD), 2026-2034
  • Table 3: Global: Antibody Drug Conjugates Market Forecast: Breakup by Target (in Million USD), 2026-2034
  • Table 4: Global: Antibody Drug Conjugates Market Forecast: Breakup by Application (in Million USD), 2026-2034
  • Table 5: Global: Antibody Drug Conjugates Market Forecast: Breakup by End User (in Million USD), 2026-2034
  • Table 6: Global: Antibody Drug Conjugates Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 7: Global: Antibody Drug Conjugates Market: Competitive Structure
  • Table 8: Global: Antibody Drug Conjugates Market: Key Players